Photorefractive treatment of myopic astigmatism by laser-assisted in situ Keratomileusis and Photorefractive Keratectomy

Main Article Content

Ahmed Mohammed Al-Samak
Sajid Yousef Shehab

Keywords

myopic astigmatism;, laser-assisted in situ keratomileusis (LASIK);, photorefractive keratectomy (PRK)

Abstract

Aim: To compare the refractive correction among patients with myopic astigmatism either by laser-assisted
in situ keratomileusis (LASIK) or photorefractive keratectomy (PRK) after 6 months.
Methods: Comparative retrospective study of 356 eyes of 196 patients were treated by laser photorefractive
correction at AL BASIRA eye Centre, Basra, Iraq to correct their refractive error with a mean age of 26.8
years (range: 18–45). Of those, 213 eyes were treated by LASIK and 143 eyes were treated by PRK. The
correction of a refractive error was done by Carl Zeiss Mel 90 machine and all operations were done by two
surgeons. The study period lasted from October 2017 to October 2019.
Results: All patients were followed for a period of 6 months, assessed their refractive correction, and found
all values to be statistically significant (P < 0.001). The refractive correction was better for the PRK group
with less undesirable effect of under correction or overcorrection.
Conclusions: Our study shows relatively superior refractive correction in patients undergoing PRK.
However, many patients suffer from postoperative pain and gradual refractive stability.
 

Abstract 155 | pdf Downloads 63 xml Downloads 0 html Downloads 0

References

1.Read SA, Collins MJ, Carney LG. A review of astigmatism and its possible genesis. Clin Exp Optom. 2007;90:5–19.
2. American Academy of Ophthalmology. https://www.aao.org/eye-health/diseases/what-is-astigmatism
3. Shortt AJ, Bunce C, Allan BD. Evidence for superiorefficacy and safety of LASIK over photorefractive
keratectomy for correction of myopia.Ophthalmology. 2006;113:1897–908.
4. Melki SA, Azar DT. LASIK complications:Etiology, management, and prevention. Surv Ophthalmol. 2001;46:95–116.
5. Reynolds A, Moore JE, Naroo SA, Moore CB, Shah S. Excimer laser surface ablation – A review.Clin Experiment Ophthalmol. 2010;38:168–82.
6. Condon PI, O’Keefe M, Binder PS. Long-termresults of laser in situ keratomileusis for high myopia: Risk for ectasia. J Cataract Refract Surg. 2007;33:583–90.
7. Binder PS. Ectasia after laser in situ keratomileusis. J Cataract Refract Surg. 2003;29:2419–29.
8.Hersh PS, Brint SF, Maloney RK, et al.Photorefractive keratectomy versus laser in situ keratomileusis for moderate to high myopia. A randomized prospective study. Ophthalmology. 998;105:1512–22. http://dx.doi.org/10.1016/S0161-
6420(98)98038-1
9. Slade SG, Durrie DS, Binder PS. A prospective,contralateral eye study comparing thin-flap LASIK(sub-bowman keratomileusis) with photorefractivekeratectomy. Ophthalmology. 2009;116:1075–82.http://dx.doi.org/10.1016/j.ophtha.2009.01.001
10. Nir Sorkin, Amir Rosenblatt, David Smadja, EyalCohen, Marcony R. Santhiago, David Varssano,etal. Early refractive and clinical outcomes ofhigh-myopic photorefractive keratectomy as analternative to LASIK surgery in eyes with high
preoperative percentage of tissue altered. https://dx.doi.org/10.1155/2019/6513143
11. Weldon W Haw, Edward E Manche. Photorefractivekeratectomy for compound myopic astigmatism.Am J Ophthalmol. 2000;130(1):12–19Mohammad Miraftab, Hassan Hashemi, andSoheila Asgari. Two-year results of femtosecond
assisted LASIK versus PRK for different severityof astigmatism. J Curr Ophthalmol. 2018;30(1):48–53. Published online 2017 Oct 9. http://dx.doi.org/10.1016/j.joco.2017.09.003
13. Alex J Shortt, Bruce DS Allan, Jennifer R Evan.Laser-assisted in-situ keratomileusis (LASIK) versusphotorefractive keratectomy (PRK) for myopia.Am J Ophthalmol. 2000;130(1):??.
14. Qasim MT, Al-Mayali HK. Investigate the relationbetween Baicalin effect and gene expressionof LH, FSH, testosterone in male ratstreated with Gemcitabine drug. Res J PharmTechnol. 2019;12(9):4135–41.
15. Qasim MT, Al-Mayali HK. The immunologicaland protective role of Baicalin in male rats treatedwith chemotherapy (Gemcitabine). J Phys Conf Ser. 2019;1234:012065.